Guggenheim analyst Michael Schmidt maintains $Revolution Medicines (RVMD.US)$ with a buy rating, and adjusts the target price from $38 to $82.
According to TipRanks data, the analyst has a success rate of 50.5% and a total average return of 17.0% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Revolution Medicines (RVMD.US)$'s main analysts recently are as follows:
Following the presentation of initial Phase 1 findings for RMC-9805 in advanced pancreatic ductal adenocarcinoma patients at the EORTC-NCI-AACR Symposium, analysts have enhanced their confidence in the potential success of RMC-6036 in the current Phase 3 study for second-line pancreatic ductal adenocarcinoma, especially after considering the updated Phase 1/1b data disclosed recently.
Following recent clinical updates on '6236 and '9805 in PDAC presented at a major scientific meeting and an investor event, analysts have expressed their pleasure with the improvement seen in the updated Phase 1 data for '6236. The first reported median Overall Survival (mOS) data reinforces the potential of '6236 to change the treatment landscape in second line and beyond Pancreatic Ductal Adenocarcinoma (PDAC). Moreover, the First-in-Human (FIH) data of '9805 in PDAC is also met with a positive view, showcasing promising signs of clinical activity and a safety profile that exceeds initial expectations.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
Guggenheim分析师Michael Schmidt维持$Revolution Medicines (RVMD.US)$买入评级，并将目标价从38美元上调至82美元。
根据TipRanks数据显示，该分析师近一年总胜率为50.5%，总平均回报率为17.0%。
此外，综合报道，$Revolution Medicines (RVMD.US)$近期主要分析师观点如下：
在欧洲癌症研究组织-新华保险-美国癌症研究协会举办的研讨会上，针对爱文思控股在爱文思控股腺癌患者中RMC-9805初始1期结果的展示后，分析师们对目前正在进行的第3期研究中RMC-6036在二线胰腺导管腺癌患者中取得成功的潜力增强了信心，尤其是在考虑了最近披露的第10/10亿期数据后。
在近期有关PDAC中'6236和'9805的临床更新在一次重大科学会议和投资者活动上展示后，分析师们对'6236最新1期数据中的改善表示满意。首次报告的中位总生存期（mOS）数据进一步强化了'6236在二线及进一步用于胰腺导管腺癌（PDAC）治疗领域中改变治疗方式的潜力。此外，'9805在PDAC中的先导研究（FIH）数据也受到了积极评价，展示了临床活性的有希望迹象和超出初步预期的安全性。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
